Zobrazeno 1 - 10
of 206
pro vyhledávání: '"TAKUYA TSUNODA"'
Autor:
Hitoshi Toyoda, Atsuo Kuramasu, Masahiro Hosonuma, Masakazu Murayama, Yoichiro Narikawa, Junya Isobe, Yuta Baba, Kohei Tajima, Eiji Funayama, Midori Shida, Yuki Maruyama, Aya Sasaki, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Sei Kobayashi, Atsushi Horiike, Noriko Hida, Takehiko Sambe, Koji Nobe, Satoshi Wada, Hitome Kobayashi, Mayumi Tsuji, Shinichi Kobayashi, Takuya Tsunoda, Yoshifumi Kudo, Yuji Kiuchi, Kiyoshi Yoshimura
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Natural killer group 2 member D ligands (NKG2DLs) are expressed as stress response proteins in cancer cells. NKG2DLs induce immune cell activation or tumor escape responses, depending on their expression. Human pancreatic cancer cells, PANC-
Externí odkaz:
https://doaj.org/article/9cc18d13b98e4eae855bec63d4c5642c
Autor:
Saeko Kashimura, Miki Sato, Takahito Inagaki, Masaoki Kin, Ryo Manabe, Sojiro Kusumoto, Atsushi Horiike, Takuya Tsunoda, Mari Kogo
Publikováno v:
Thoracic Cancer, Vol 15, Iss 28, Pp 2049-2060 (2024)
Abstract Background The relationship between the combination of platelet count and neutrophil‐lymphocyte ratio (COP‐NLR) and prognosis in patients with advanced non‐small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor (ICI) c
Externí odkaz:
https://doaj.org/article/fcaaca174d4f4c25a101f80f1ed991cb
Autor:
Yuya Hirasawa, Yutaro Kubota, Emiko Mura, Risako Suzuki, Toshiaki Tsurui, Nana Iriguchi, Tomoyuki Ishiguro, Ryotaro Ohkuma, Masahiro Shimokawa, Hirotsugu Ariizumi, Atsushi Horiike, Satoshi Wada, Takeshi Yamashita, Tomotake Ariyoshi, Satoru Goto, Koji Otsuka, Masahiko Murakami, Yuji Kiuchi, Kiyoshi Yoshimura, Takuya Tsunoda
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionImmune checkpoint inhibitors (ICIs) have emerged as a promising treatment option for esophageal cancer (EC). Although ICIs enable long-term survival in some patients, the efficacy of ICIs varies widely among patients. Therefore, predictiv
Externí odkaz:
https://doaj.org/article/ec9c13c60c4d45eb834f44c57b5372fe
Autor:
Masakazu Murayama, Masahiro Hosonuma, Atsuo Kuramasu, Sei Kobayashi, Akiko Sasaki, Yuta Baba, Yoichiro Narikawa, Hitoshi Toyoda, Junya Isobe, Eiji Funayama, Kohei Tajima, Aya Sasaki, Yuki Maruyama, Yoshitaka Yamazaki, Midori Shida, Kazuyuki Hamada, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Atsushi Horiike, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Shinichi Kobayashi, Toshikazu Shimane, Takuya Tsunoda, Hitome Kobayashi, Yuji Kiuchi, Kiyoshi Yoshimura
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The low response rate of immune checkpoint inhibitors (ICIs) is a challenge. The efficacy of ICIs is influenced by the tumour microenvironment, which is controlled by the gut microbiota. In particular, intestinal bacteria and their metabolit
Externí odkaz:
https://doaj.org/article/7f87f822bfdf411aabf1cc2f6ca5007b
Autor:
Takashi Shimizu, Eisuke Inoue, Ryotaro Ohkuma, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/1afbfe292d48439c963acc6084437cfe
Autor:
Takashi Shimizu, Eisuke Inoue, Ryotaro Ohkuma, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionCurrently, first-line immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) inhibitors, are utilized as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand-
Externí odkaz:
https://doaj.org/article/79df360ee61b4247bc78ebaffe4da883
Autor:
Yuta Nio, Hiroo Ishida, Natsumi Matsumoto, Sojiro Kusumoto, Yutaro Kubota, Takuya Tsunoda, Yasutsuna Sasaki, Ken-ichi Fujita
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Gefitinib is recommended as a first-line treatment option for elderly patients with non-small cell lung cancer (NSCLC). Because no pharmacokinetics of gefitinib have been examined, we prospectively assessed the pharmacokinetics of
Externí odkaz:
https://doaj.org/article/d782a4040fdf4d7288eb955e6906f4fd
Autor:
Ryotaro Ohkuma, Sakiko Miura, Satoshi Muto, Yoshitaka Toyomasu, Yuki Fujimoto, Katsuaki Ieguchi, Nobuyuki Onishi, Takashi Shimizu, Makoto Watanabe, Daisuke Takayanagi, Tsubasa Goshima, Atsushi Horiike, Kazuyuki Hamada, Hirotsugu Ariizumi, Masahiro Shimokawa, Yuya Hirasawa, Tomoyuki Ishiguro, Risako Suzuki, Nana Iriguchi, Toshiaki Tsurui, Emiko Mura, Sachiko Takenoshita, Kazuki Numajiri, Naoyuki Okabe, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Toshiki Yajima, Hideyuki Ishida, Hiroyuki Suzuki, Toshiko Yamochi, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionProgrammed cell death ligand 1 (PD-L1) expression in tumor tissues is measured as a predictor of the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in many cancer types. PD-L1 expression is evaluated by immunohistochemical st
Externí odkaz:
https://doaj.org/article/ae7a3794a1b04272bd831501907f335c
Autor:
Risako Suzuki, Kazuyuki Hamada, Ryotaro Ohkuma, Mayumi Homma, Toshiaki Tsurui, Nana Iriguchi, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Yutaro Kubota, Atsushi Horiike, Kiyoshi Yoshimura, Satoshi Wada, Toshiko Yamochi, Takuya Tsunoda
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundCancer of unknown primary (CUP) is a malignant tumor without a known primary lesion with a frequency of 3−5%. It can be divided into favorable and unfavorable prognosis subsets. While recommended treatments are available for the former gr
Externí odkaz:
https://doaj.org/article/e2477a64a1da4c75b2af29bfc6cb2d4a
Autor:
Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Yuji Kiuchi, Shinichi Kobayashi, Atsuo Kuramasu, Atsushi Horiike, Yun-Gi Kim, Takuya Tsunoda, Kiyoshi Yoshimura
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionImmune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays a major role in the cancer microenvironment, affecting treatment response. The gut microbiota is highly individual, and varies with factors, su
Externí odkaz:
https://doaj.org/article/3baf4a74bec646c1a17af2830c7a875b